Impact of controlled ice nucleation and lyoprotectants on nanoparticle stability during Freeze-drying and upon storage.

Amphotericin B Controlled ice nucleation Freeze-drying Freezing rate Lyophilization Nanoparticles

Journal

International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127

Informations de publication

Date de publication:
25 Jun 2023
Historique:
received: 25 02 2023
revised: 21 05 2023
accepted: 23 05 2023
medline: 14 6 2023
pubmed: 29 5 2023
entrez: 28 5 2023
Statut: ppublish

Résumé

The freezing step of the lyophilization process can impact nanoparticle stability due to increased particle concentration in the freeze-concentrate. Controlled ice nucleation is a technique to achieve uniform ice crystal formation between vials in the same batch and has attracted increasing attention in pharmaceutical industry. We investigated the impact of controlled ice nucleation on three types of nanoparticles: solid lipid nanoparticles (SLNs), polymeric nanoparticles (PNs), and liposomes. Freezing conditions with different ice nucleation temperatures or freezing rates were employed for freeze-drying all formulations. Both in-process stability and storage stability up to 6 months of all formulations were assessed. Compared with spontaneous ice nucleation, controlled ice nucleation did not cause significant differences in residual moisture and particle size of freeze-dried nanoparticles. The residence time in the freeze-concentrate was a more critical factor influencing the stability of nanoparticles than the ice nucleation temperature. Liposomes freeze-dried with sucrose showed particle size increase during storage regardless of freezing conditions. By replacing sucrose with trehalose, or adding trehalose as a second lyoprotectant, both the physical and chemical stability of freeze-dried liposomes improved. Trehalose was a preferable lyoprotectant than sucrose to better maintain the long-term stability of freeze-dried nanoparticles at room temperature or 40 °C.

Identifiants

pubmed: 37245738
pii: S0378-5173(23)00504-5
doi: 10.1016/j.ijpharm.2023.123084
pii:
doi:

Substances chimiques

Ice 0
Liposomes 0
Trehalose B8WCK70T7I
Sucrose 57-50-1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

123084

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Xiuling Lu reports financial support was provided by Center for Pharmaceutical Processing Research.

Auteurs

Wei-Chung Luo (WC)

Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA.

William Zhang (W)

Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA.

Rachel Kim (R)

Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA.

Heather Chong (H)

Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA.

Sajal M Patel (SM)

Dosage Form Design & Development, Biopharmaceutical Development, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD 20878, USA.

Robin H Bogner (RH)

Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA.

Xiuling Lu (X)

Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA. Electronic address: xiuling.lu@uconn.edu.

Articles similaires

Tumor Microenvironment Nanoparticles Immunotherapy Cellular Senescence Animals
Cobalt Azo Compounds Ferric Compounds Polyesters Photolysis
Neoplastic Stem Cells Animals Humans Aldehyde Dehydrogenase Tretinoin

Classifications MeSH